

## **Traitements préventifs et curatifs possibles lors d'infection à SARS-CoV-2 (COVID-19) au 11 décembre 2020**

Informations données sans garantie absolue et à vérifier le cas échéant auprès d'un médecin généraliste ou interniste de confiance.

### **A titre préventif :**

Vit. C, D, Zinc et Acétylcystéine.

Penser aussi aux infusions d'Artemisia !

### **Protocole IHU-Marseille :**

Hydroxy-chloroquine, Azithromycine et Zinc

### **Protocole Australien du Prof. Thomas Borody :**

Ivermectine, Doxycycline et Zinc

<https://www.youtube.com/watch?v=93jI7GI3yic>

Gastroenterologist Professor Thomas Borody says the Australian government should allow the clinical trials of a drug he says is “amazingly effective” in treating the deadly coronavirus COVID-19. Professor Borody says Ivermectin, used in conjunction with two other drugs, has so far been extremely successful in treating the deadly pathogen. The drug is Federal Drug Agency and World Health Organisation approved; it is widely used for parasitic infections. However, Professor Borody told Sky News despite early result showing the drug is a successful COVID-19 treatment, he has been met with a “very negative reaction” by the federal government when he suggests the drug should be subjected to rigorous clinical trials.

<https://www.youtube.com/watch?v=MZRyzEhh2nk>

Well-Respected Australian Researcher: Consider Triple Therapy ([#Ivermectin](#), Zinc, [#Doxycycline](#)) for COVID-19: Thomas Borody touts FDA and Australian food and drug authority TGA approved Ivermectin, which he reports to use regularly in his hospital as it evidences positive results for [#COVID19](#) and should be used immediately to fight the pandemic. The developer of the world's first cure for peptic ulcers, which saved millions of lives worldwide, employed the same methodology to come up with the Ivermectin triple therapy. With over 30 formal clinical trials, many dozens of observational real-world initiatives and hundreds to possibly thousands of doctors already using the medicine, a particular momentum gains speed for additional randomized controlled trials and, just as importantly, a more serious dialogue about the potential of this approach for pragmatic and economical treatment options for COVID-19.